The Rise of Cannabis Vaping: How the Weed Industry Learned From Big Nicotine

In a dispensary in Denver, Colorado, the display case looks indistinguishable from a vape shop: rows of colorful cartridges in flavors like Pineapple Express, Blue Dream, and Wedding Cake, each designed to attach to a standardized 510-thread battery that could just as easily power a nicotine vape. The packaging is glossy, the strain names are evocative, and the marketing on Instagram features the same aspirational lifestyle imagery that characterized nicotine vaping's golden age. The cannabis vaping industry, barely a decade old in legal markets, has followed nicotine vaping's trajectory with eerie precision—rapid growth, youth appeal, flavor innovation, regulatory scrambling, and now, an epidemic of concern. The difference is that cannabis vaping hasn't yet had its JUUL moment. But it may be coming.

The convergence of nicotine and cannabis vaping is technological, cultural, and regulatory. The same Shenzhen manufacturers that produce nicotine vaping hardware produce cannabis hardware—the cartridges, batteries, and heating elements are largely interchangeable. The same social media platforms that amplified nicotine vaping content now host cannabis vaping influencers with millions of followers. And the same regulatory vacuum that allowed nicotine vaping to explode before regulators could respond is replicated in cannabis, where legalization has raced ahead of the public health infrastructure needed to monitor and respond to emerging risks. The result is a replay of recent history, with the stakes arguably higher: cannabis vaping involves a psychoactive substance with its own set of developmental risks for adolescent brains, layered on top of the inhalation risks common to all vaping products.

The 2019 EVALI outbreak—e-cigarette or vaping product use-associated lung injury—was a preview of what can go wrong when a vaping market goes unregulated. The outbreak, which killed 68 people and hospitalized nearly 3,000 in the United States, was ultimately traced to vitamin E acetate used as a cutting agent in illicit THC cartridges, not to legal, regulated cannabis or nicotine products. But the public understanding of the outbreak was profoundly different: many consumers concluded that 'vaping is dangerous,' without distinguishing between legal and illicit, nicotine and cannabis, regulated and unregulated. The EVALI crisis demonstrated that the nicotine and cannabis vaping markets are linked in the public mind, and that a failure of regulation in one can have devastating consequences for both. It also demonstrated, to anyone paying attention, that the regulatory frameworks for inhaled cannabis products were dangerously underdeveloped.

The youth dimension of cannabis vaping is particularly concerning because it compounds two risk factors that are each independently serious. Adolescent cannabis use is associated with cognitive effects (impaired memory, attention, and executive function), increased risk of psychotic disorders in genetically vulnerable individuals, and the potential for cannabis use disorder—a condition that affects roughly 9% of cannabis users overall and up to 17% of those who initiate in adolescence. Adolescent vaping, independent of the substance being vaped, involves exposure to heated aerosol with uncertain long-term respiratory effects and the behavioral reinforcement of a hand-to-mouth ritual that normalizes inhalation-based substance use. When these risk profiles are combined—adolescents vaping cannabis—the public health concern is not additive but multiplicative. Yet surveillance systems are only beginning to disaggregate cannabis vaping from nicotine vaping in youth surveys, and the data that exists suggests that cannabis vaping among adolescents has been rising alongside, and in some demographics surpassing, nicotine vaping.

The regulatory patchwork for cannabis vaping is even more fragmented than for nicotine. In the United States, cannabis remains federally illegal, which means the FDA has no authority over cannabis vaping products (except when they're involved in an acute outbreak like EVALI). State-level cannabis regulators, who oversee legal markets, have focused primarily on product safety (testing for pesticides, heavy metals, and residual solvents) and packaging requirements (child-resistant containers, THC content labeling). They have not, for the most part, regulated the aspects of cannabis vaping products that most directly affect public health: flavor restrictions, marketing limits, potency caps on THC concentration, or device safety standards. The most basic questions—what's a safe temperature to heat cannabis oil, what compounds are produced at different temperatures, what are the long-term respiratory effects of daily cannabis vaping—remain largely unanswered and largely unfunded.

The cannabis industry's response to these concerns has followed a familiar script. Industry advocates emphasize that legal, regulated products are safer than illicit ones (true, but incomplete), that cannabis vaping provides a smoke-free alternative for medical patients (true for some, marketing for others), and that regulation should target bad actors rather than restricting consumer choice (the same argument the nicotine vaping industry made before flavor bans and PMTA requirements). The industry has also begun to adopt the language of 'wellness' and 'harm reduction' that characterizes the modern nicotine market—positioning cannabis not as an intoxicant but as a health and lifestyle enhancement product. The commercialization of cannabis is following the trajectory of tobacco commercialization in the early 20th century: a product with genuine risks and genuine benefits is being optimized for mass-market appeal by an industry whose incentives are commercial, not therapeutic.

The policy opportunity, for jurisdictions that are still in the process of legalizing cannabis or refining their regulatory frameworks, is to learn from nicotine's regulatory failures rather than repeat them. This means establishing product standards (limits on additives, cutting agents, and potentially THC concentration in vape cartridges), marketing restrictions (no youth-targeted advertising, no unsubstantiated health claims, no social media influencers), retail access controls (age-gated dispensaries, not convenience stores), and robust post-market surveillance that can detect emerging harms before they become outbreaks. It means funding research on the health effects of cannabis vaping—both short-term (EVALI-like risks) and long-term (respiratory, cognitive, cardiovascular)—at a scale commensurate with the rapidly growing population of users. And it means integrating cannabis regulation with nicotine regulation, recognizing that the two markets are converging in both product technology and consumer behavior. The alternative—regulating cannabis vaping with the same delayed, reactive approach that characterized nicotine vaping regulation—will predictably reproduce the same outcomes. The industry is already writing the playbook. Regulators have the advantage of having read it before.